Study Finds Tech is Number One Industry for Workplace Drinking

Tech.Co

Now, a new study has pulled tech drinking culture back into the spotlight. The tech world, the study found, is the single industry most likely to allow or sponsor alcohol consumption in the workplace.

Study 174

Missed Expectations and The Eighty Percent Acquisition Rule

Berkonomics

But it is within the range of experience by many of us professional investors, and with those who have acted as brokers, serial purchasers or consultants for acquisitions.

Missed Expectations and The Eighty Percent Acquisition Rule

Berkonomics

But it is within the range of experience by many of us professional investors, and with those who have acted as brokers, serial purchasers or consultants for acquisitions.

The Eighty Percent Acquisition Rule

Berkonomics

But it is within the range of experience by many who have acted as brokers, serial purchasers or consultants for acquisitions. The answer is that the most sophisticated buyers have experience in integrating an acquisition successfully into an enterprise and those successes are the most visible models for others to follow. Eighty percent of all businesses purchased by another company or by a new investor-operator fail to meet the stated expectations of the buyer after one year.

Study: $48 Billion In Value Created Over 15 Years In SoCal IT VC-Backed Firms

socalTECH

A new study of the financial outcomes for Southern California venture-backed companies in the IT sector finds that approximately $48 billion in value has been created by those companies over the period 1995-2009. The study, conducted by Jon Funk of OceanRoad Partners , includes data from socalTECH.com's proprietary venture database , Dow Jones/VentureSource, and Greg Martin of Redpoint Ventures.

Study 160

Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More

Xconomy

Merck Nasdaq NEA Nektar Therapeutics New Enterprise Associates Novartis Nuevolution NYSE opioid painkiller PatientsLikeMe pembrolizumab pricine Pricing regulation Rene Russo RNA Royalty Scott Gottlieb SCOTUS SMA Spinal Muscular Atrophy Study subsidiary T-cell therapy Tocagen US Supreme Court value Vas Narasimhan VC Venture Capital Voyager Therapeutics watchdog Zolgensma

Study 63

Negative Customer Acquisition Costs - Creative Startup Marketing Ideas - Eric David Greenspan

SoCal CTO

Some days I respond to questions asked by folks like yourself, the press, or an entity doing a case study, i.e. Citrix, RIM, USC. Our new customer acquisition has grown and our costs have plummeted. We are actually getting paid now to obtain customers, so our customer acquisition costs are now negative. A negative customer acquisition cost! My company and I are a perfect case study for the Tech Council affiliation.

Ideas 163

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

Xconomy

[ Editor’s note: Ben Fidler and Sarah de Crescenzo coauthored this report.] It is here, and then it is gone. But by the time everyone staggers to the airport or back home to sleep in their own beds, the annual few days of the J.P. Morgan Healthcare Conference and everything that mushrooms around it seem just as long as the holiday break—a distant memory!—that —that came just before. In 2020 (yes, that’s really a year), San Francisco might have a new mayor.

Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More

Xconomy

It was a busy week. If we had to choose a theme, it was all about getting together. Two huge drug companies, AbbVie and Allergan, said they’d be better as one. Two more huge drug companies, Celgene and Bristol-Myers Squibb, learned they would have to leave a big product behind if they want to merge. Twenty Democrats came together across two evenings to bash huge drug companies (among other topics), angling to be the one to challenge Donald Trump next year.

Viracta, Neurelis & More: The Latest in San Diego Biotech

Xconomy

Even as all eyes were on the American Society of Hematology (ASH) conference in downtown San Diego this week, other biotech companies were staying busy. Let’s get caught up with the latest life sciences news in San Diego. Check out Xconomy’s ASH coverage here and here.) —Viracta Therapeutics has raised $10 million from China’s Salubris Pharmaceuticals as part of a larger ongoing financing round. The San Diego biotech is developing therapies for cancers related to the Epstein-Barr virus.

Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More

Xconomy

The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer, but the bigger picture is that the field is moving fast. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options? We explored that question in our coverage.

News 46

Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More

Xconomy

One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its complicated logistics, side effects, and potential high cost, it won’t be for everyone who experiences the condition— 1 of every 9 U.S. women giving birth. But at least it’s an option.

News 46

Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More

Xconomy

The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9 billion, the price Gilead Sciences is paying for Kite Pharma and its cancer-fighting cell therapy pipeline.

Ideas 55

Bio Roundup: $1B Deals, Data Bumps, Acorda’s Lumps, Generic OKs & More

Xconomy

With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences news from the nation’s capital. The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices.

Everything you do adds or reduces company value

Berkonomics

But each commitment of resources of any substantial size for acquisition of new products, talent, even new companies, changes the value of your enterprise perhaps to a great degree. Should I make an acquisition to increase value? Odds that an acquisition will be a success.

By the Numbers: The Returns from Southern California IT IPO's 1995-2009

socalTECH

On March 10, socaltech.com profiled a study of the financial outcomes of 700+ southern California IT startups from 1995-2009 completed by Jon Funk of OceanRoad Partners and others. Tags: oceanroad study acquisition merger california southern This Insights and Opinions column by Jon is the first in an occasional series delving deeper into the data.

The brains behind one of marketing’s biggest hits are out to reshape the industry again… with direct mail

TechCrunch LA

According to study from the Direct Marketing Association, direct mail campaigns rang up $46 billion from advertisers and companies in 2014, and Fink and his co-founder are hoping that number will climb.

Startups Weekly: VCs are drunk on beverage startups

TechCrunch LA

For one, because millennials, according to various studies, are consuming less alcohol than previous generations and are therefore seeking non-alcoholic beverage alternatives. As Amex scoops up Resy, a look at its acquisition history .

Illumina Cuts Forecasts As Consumer Tests, Genomics Initiatives Lag

Xconomy

The news reflects a slowdown in the demand for mail-in genetic testing kits and a lag in the rollout of some of the government-led population studies for which Illumina provides DNA sequencing tools.

Study 62

BioDuro Acquires Molecular Response

socalTECH

According to BioDuro, Molecular Response has a biobank of over 100,000 viable tumor specimens, which are used for drug discovery, oncology, and immunooncology studies. bioduro molecular response merger acquisition biotech lifescience contract research bioscience tumor oncology

Study 122

Ligand Buys Programs From Selexis SA

socalTECH

Ligand--which develops a range of pharmaceuticals--said that it acquired a number of programs in various stages of development, ranging from preclinical through Phase 3 studies. ligand selexis merger acquisition lifescience biotech pharmacueitcalSan Diego-based Ligand Pharmaceuticals announced this morning that it has acquired more than 15 different programs from Selexis SA , for $4M in cash.

Study 131

Amgen Licenses Rights To Multiple Myeloma Drug

socalTECH

The compound is currently in Phase I studies. amgen multipe myeloma merger acquisition oncology immunology biotech lifescience licensing micrometThousand Oaks-based Amgen and Boehringer Ingelheim said on Thursday that Amgen has acquired the global development and commercial rights for an immuno-oncology drug for treating multiple myeloma.

Allergan Buys Vicept Therapeutics

socalTECH

Vicent is currently in Phase II studies for its lead compound. rosacea lifescience biotech acquisition merger therapeutics vicept allerganIrvine-based Allergan said this morning that it has acquired Vicept Therapeutics , a developer of a compound for treating the erythema of rosacea.

Study 181

California Led Q1 IPO Pipeline

socalTECH

New information released in a study of the IPO pipeline, finds that California continues to be the most active market in terms of initial public offerings. According to the Renst & Young LLP US IPO Pipeline study, California had 25 companies looking to raised $2.2 california merger acquisition southern public exit angeles

Study 126

Think of your exit as you commit your resources along the way.

Berkonomics

But each commitment of resources of any substantial size for acquisition of new products, talent, even new companies, changes the value of your enterprise perhaps to a great degree. Let’s analyze the effect of a potential acquisition upon the value of your company. There are many reasons a company finds to make an acquisition. Each decision you make to commit resources affects the future value of the business to some degree.

Amgen Buys deCODE Genetics

socalTECH

deCODE Genetics has been using studies of the Icelandic population to help uncover the specific genes and genetic risk factors in diseases. amgen decode genetics merger acquisition genes research lifescience biotechThousand Oaks-based biotech Amgen is acquiring Iceland-based deCODE Genetics , in a deal worth $415M in cash, the two companies announced this morning. deCODE Genetics is a provider of human genetic research which was founded in 1996.

Connexity Buys Hitwise

socalTECH

Connexity also said its private equity owner, Symphony Technology Group, is acquiring Experian's Simmons division, the publisher of the consumer research database, the National Consumer Study (NCS). connexity hitwise experian merger acquisition symphony technology group marketing bizrateLos Angeles-based digital marketer Connexity has acquired consumer data collection company Hitwise , from parent company Experian , the company said this morning.

Study 109

Sorrento Therapeutics Spins Off Animal Health Company

socalTECH

The company said the move came after early Phase 1 clinical studies of its compound resiniferatoxin (RTX) showed promise in treating pain in both humans and dogs. sorrento therapeutics lifescience biotech pain cancer oncology veterinary spinout merger acquisition animal arkanimal San Diego-based Sorrento Therapeutics , which develops treatments for cancer and treatment of pain, is spinning off a new company focused on animal health, the company announced this morning.

Why You Can’t Get Serious About Productivity Unless You Optimize How Your People Use Your Space

Both Sides of the Table

We see companies that do large acquisitions and have to figure out how to consolidate companies and staff. I fund startups for a living and before that I ran two software startups that I founded.

Is Your Organization Ready to Become an Ecosystem Driver?

Xconomy

In a study conducted at MIT Sloan’s Center for Information Systems Research (CISR), we found that only 12 percent of large companies (with revenues more than $1 billion) are ecosystem drivers. – Are you great at partnerships and acquisitions?

San Diego Innovation Economy Extended Gains in 2015: Connect Report

Xconomy

The annual study draws data from a variety of public and private sources, including the Kansas City, MO-based Kauffman Foundation, which ranked San Diego ninth on its startup activity index, based on measures of startup density and entrepreneurs in a particular region.

10 Reasons To Start A Company In An Economic Downturn

InfoChachkie

According to financial columnist Daniel Solin, “One large study looked at more than 15,000 predictions by 237 market timing newsletters over a 12-year period. At the end of the period studied, 94.5%

American Entrepreneurs – Be Happy You Are Not In Spain

InfoChachkie

After studying at UC Santa Barbara''s entrepreneurial program , he returned to Spain, excited to start a venture and make a positive impact on his homeland. A version of this article previously appeared in Forbes.

Southern California Linked IPOs Grow

socalTECH

In fact, a recent study released by Ernst & Young found that there were eight companies in Southern California, out of 22 total in California, who were lined up for an IPO in Q4. offering investment exit acquisition merger california southernThe number of Southern California related initial public offerings is growing steadily upwards, as Gevo --originally started in Pasadena, and based on technology out of Caltech and UCLA--hit the market this morning.

Bio Roundup: Ex-Kiters Say Allo, NASH Cash & Data, Alkermes No & More

Xconomy

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. Happy Friday, everyone. We’ll start this week with biotech deals, one featuring a couple of CAR-T heavyweights who have re-emerged after selling Kite Pharma for $12 billion.

Study 48